Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

20.25 +0.51 (+2.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
How Is The Market Feeling About Catalyst Pharmaceuticals?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation
Catalyst Pharmaceuticals (CPRX) is a top GARP stock with strong growth, excellent profitability, and an attractive valuation, making it a compelling long-term investment. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate
Catalyst Pharmaceuticals (CPRX) excels in growth, profitability, and financial health, making it a top-quality stock for long-term investors according to the Caviar Cruise screen. 
Via Chartmill
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech
Catalyst Pharmaceuticals (CPRX) is a strong value stock with low P/E ratios, high profitability, zero debt, and impressive growth, offering a solid margin of safety. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) offers strong growth, fair valuation, and solid financials, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Fits Louis Navellier’s Growth Investing Strategy with Strong Earnings Momentum and Rising Sales
Louis Navellier’s growth investing strategy highlights stocks like Catalyst Pharmaceuticals (CPRX), which shows strong earnings momentum, rising sales, and high profitability. CPRX meets key criteria,... 
Via Chartmill
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential
Combine technical & fundamental analysis to spot growth stocks like Catalyst Pharmaceuticals (CPRX), showcasing strong financials & breakout potential. 
Via Chartmill
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential
Catalyst Pharmaceuticals (CPRX) is a value stock with strong fundamentals—low P/E, zero debt, high profitability, and robust growth, making it a standout in biotech. 
Via Chartmill
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth stocks. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender for Growth Investors
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors. 
Via Chartmill
Peering Into Catalyst Pharmaceuticals's Recent Short Interest
 
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a promising technical setup, making it a stock to watch. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Rare Biotech With Undervalued Potential
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks. 
Via Chartmill
Is Catalyst Pharmaceuticals Gaining or Losing Market Support?
 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Quarter
 
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A CANSLIM Candidate With Strong Growth Metrics
CATALYST PHARMACEUTICALS (CPRX) meets key CANSLIM criteria with strong earnings growth, high profitability, and market-leading relative strength. A debt-free balance sheet adds appeal. 
Via Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors
CATALYST PHARMACEUTICALS INC (CPRX) shows strong earnings growth, high profitability, and solid cash flow, making it a standout for growth investors. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and Value
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.